Altimmune to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Altimmune (Nasdaq: ALT) said company management will attend two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 10:00 a.m. ET, and a Jefferies Global Healthcare Conference fireside chat on November 20, 2025 at 9:30 a.m. GMT. Management will be available for one-on-one meetings. Both sessions will be webcast and accessible via the Events section of the company's website.
Positive
- None.
Negative
- None.
News Market Reaction 12 Alerts
On the day this news was published, ALT declined 0.27%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.4% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $981K from the company's valuation, bringing the market cap to $362M at that time.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:
- Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025
Fireside Chat at 10:00 a.m. ET
- Jefferies Global Healthcare Conference
Thursday, November 20, 2025
Fireside Chat at 9:30 a.m. GMT
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Elliot Fox
Real Chemistry
efox@realchemistry.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) present at the Stifel 2025 Healthcare Conference?
What time is Altimmune's (ALT) fireside chat at the Jefferies Global Healthcare Conference?
How can investors watch Altimmune (ALT) conference presentations in November 2025?
Will Altimmune (ALT) management be available for meetings at the November 2025 conferences?
Which investor conferences will Altimmune (ALT) attend in November 2025?
